UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 9.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 113,229 shares of the biopharmaceutical company's stock after selling 12,241 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.20% of Agios Pharmaceuticals worth $5,031,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Marshall Wace LLP raised its stake in Agios Pharmaceuticals by 307.8% during the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company's stock worth $48,887,000 after purchasing an additional 855,739 shares during the period. Frazier Life Sciences Management L.P. raised its position in shares of Agios Pharmaceuticals by 66.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company's stock valued at $37,600,000 after buying an additional 348,808 shares during the period. Candriam S.C.A. purchased a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at approximately $13,922,000. D. E. Shaw & Co. Inc. lifted its holdings in Agios Pharmaceuticals by 87.3% in the second quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company's stock valued at $29,245,000 after acquiring an additional 316,100 shares during the last quarter. Finally, Panagora Asset Management Inc. purchased a new position in Agios Pharmaceuticals in the second quarter worth approximately $7,540,000.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Royal Bank of Canada lifted their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a research report on Tuesday. Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Scotiabank increased their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research note on Monday. Raymond James reissued an "outperform" rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Finally, Leerink Partners downgraded shares of Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $60.00 to $56.00 in a report on Friday, September 27th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $56.33.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO traded down $5.20 during mid-day trading on Thursday, hitting $38.17. The company had a trading volume of 1,707,869 shares, compared to its average volume of 714,831. The company has a market capitalization of $2.18 billion, a PE ratio of 3.51 and a beta of 0.80. The business's 50-day simple moving average is $50.12 and its 200 day simple moving average is $46.65. Agios Pharmaceuticals, Inc. has a 1-year low of $20.96 and a 1-year high of $62.58.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of the firm's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. This trade represents a 11.20 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.